⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26247580 | 1.00 | — | — | |
| SCHEMBL9188293 | 1.00 | — | — | |
| SCHEMBL30585369 | 1.00 | — | — | |
| SCHEMBL894866 | 1.00 | — | — | |
| SCHEMBL26247587 | 1.00 | — | — | |
| SCHEMBL26247584 | 1.00 | — | — | |
| SCHEMBL8609056 | 0.99 | — | — | |
| SCHEMBL13743071 | 0.94 | — | — | |
| SCHEMBL11667006 | 0.88 | — | — | |
| SCHEMBL1492018 | 0.88 | KCNA5 (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197866-A1 | Treatment Of Liver Disease With Mitochondrial Glycerol-3-Phosphate Acyltransferase (GPAM) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2025-06-19 | — | — | US | claimed |
| US-12540115-B2 | Inhibitors of phospholipid synthesis and methods of use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250197866-A1 | Treatment Of Liver Disease With Mitochondrial Glycerol-3-Phosphate Acyltransferase (GPAM) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12215322-B2 | Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4297772-A1 | TREATMENT OF LIVER DISEASE WITH MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE (GPAM) INHIBITORS | Regeneron Pharmaceuticals, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-116867510-A | Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors | 雷杰纳荣制药公司 | 2023-10-10 | — | — | CN | disclosed |
| US-11702394-B2 | Inhibitors of phospholipid synthesis and methods of use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702394-B2 | Inhibitors of phospholipid synthesis and methods of use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220315528-A1 | INHIBITORS OF PHOSPHOLIPID SYNTHESIS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-10-06 | — | — | US | disclosed |
| US-20220307032-A1 | Treatment Of Liver Disease With Mitochondrial Glycerol-3-Phosphate Acyltransferase (GPAM) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2022-09-29 | — | — | US | disclosed |
| WO-2022182985-A1 | TREATMENT OF LIVER DISEASE WITH MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE (GPAM) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
| WO-2021035031-A1 | INHIBITORS OF PHOSPHOLIPID SYNTHESIS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-02-25 | — | — | WO | disclosed |
| US-20210002240-A1 | INHIBITORS OF PHOSPHOLIPID SYNTHESIS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-01-07 | — | — | US | disclosed |
| EP-3755313-A1 | INHIBITORS OF PHOSPHOLIPID SYNTHESIS AND METHODS OF USE | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2020-12-30 | — | — | EP | disclosed |
| WO-2019165232-A1 | INHIBITORS OF PHOSPHOLIPID SYNTHESIS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-08-29 | — | — | WO | disclosed |
| CN-102395270-B | Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same | FASGEN INC | 2014-11-12 | — | — | CN | disclosed |
| WO-2013155528-A2 | METHODS FOR REDUCING BRAIN INFLAMMATION, INCREASING INSULIN SENSITIVITY, AND REDUCING CERAMIDE LEVELS | FASGEN, INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| US-20120083471-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same | FAS SECURED CREDITORS HOLDCO, LLC | 2012-04-05 | — | — | US | disclosed |
| EP-2303013-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, METHODS OF USE FOR SAME, AND METHODS FOR PREPARING SAME | Fasgen, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010005922-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, METHODS OF USE FOR SAME, AND METHODS FOR PREPARING SAME | FASGEN, INC. (US) | 2010-01-14 | — | — | WO | disclosed |